Automated Classification of At-home SARS-CoV-2 Lateral Flow Assay Test Results using Image Matching and Transfer Learning: multiple-pipeline study

Author:

Safarzadeh MeysamORCID,Herbert Carly,Wong Steven Koon,Stamegna Pamela,Guilarte-Walker Yurima,Wright Colton,Suvarna Thejas,Nowak Chris,Kheterpal Vik,Pandey Shishir,Wang Biqi,Lin Honghuang,O’Connor Laurel,Hafer Nathaniel,Luzuriaga Katherine,Manabe Yuka,Broach John,Zai Adrian H,McManus David D,Du Xian,Soni Apurv

Abstract

AbstractIntroductionRapid antigen testing for SARS-CoV-2 is an important tool for the timely diagnosis of COVID-19, especially in at-home settings. However, the interpretation of test results can be subjective and prone to error. We describe an automated image analysis pipeline to accurately classify test types and results without human intervention using a dataset of 51,274 rapid antigen test images across three distinct test card brands.MethodsThe proposed method classifies participant-submitted images into four categories: positive for SARS-CoV-2, negative for SARS-CoV-2, invalid/uncertain, and unclassifiable. The model includes four stages: test card classification and region of interest detection using image-matching algorithms, elimination of invalid results using a developed Siamese neural network, and test result classification using transfer learning.ResultsThe model accuracy was very good for test-card classification (100%), region of interest detection (83.5%), and identification of invalid results ranging from 95.6% to 100% for different test types. Performance of the model for test result classification varied by tests; the model’s sensitivity, specificity, and precision for Abbott BinaxNOW™ was 0.761, 0.989, and 0.946, BD Veritor™ At-Home COVID-19 Test was 0.955, 0.993, and 0.877, and for QuickVue® At-Home OTC COVID-19 Test was 0.816, 0.988, and 0.930.ConclusionThe proposed method improved the interpretation of rapid antigen tests, particularly in invalid result detection compared to human-read, and offers a great opportunity for standardization of rapid antigen test interpretation and for providing feedback to participants with invalid tests.

Publisher

Cold Spring Harbor Laboratory

Reference23 articles.

1. “World Health Organization declares global emergency_ A review of the 2019 novel coronavirus (COVID-19) | Elsevier Enhanced Reader.” Accessed: Sep. 16, 2022. [Online]. Available: https://reader.elsevier.com/reader/sd/pii/S1743919120301977?token=D0D03718274003A59DD6FFFC4F927626F37B1BAC7D007F0C2644BFECA8F4A6DD4278BAA9AA883514D187651ECF14D69B&originRegion=us-east-1&originCreation=20220917024212

2. Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview

3. COVID-19 Point-of-Care Diagnostics: Present and Future

4. C. for D . and R. Health , “In Vitro Diagnostics EUAs - Antigen Diagnostic Tests for SARS-CoV-2,” FDA, Aug. 2023, Accessed: Aug. 31, 2023. [Online]. Available: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2

5. Scaling up COVID-19 rapid antigen tests: promises and challenges

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3